📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 17:51
666 analysed today
666
Today
133,555
All-time analysed
40,122
Positive
6,284
Negative
79,331
Neutral
7,750
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Abate As Industries Reports Rs 22.82 Cr Q1 Revenue, Proposes Major Healthcare Expansion
Abate As Industries reported Q1 FY27 revenue of Rs 22.82 Cr and a net profit of Rs 2.24 Cr. The board has proposed a significant expansion of its Memorandum of Association (MoA) to include super-specialty hospitals, diagnostic centers, and digital healthcare platforms. Key leadership moves include the re-appointment of Executive Director Dr. Muhammed Swadique for a 5-year term and the appointment of a new Independent Director with 20+ years of international experience. Notably, promoter holding has recently increased from 27.57% to 32.42%, signaling internal confidence.
Confidence: HIGH
What changedThe company is expanding its legal business scope from general healthcare to a comprehensive ecosystem including super-specialty hospitals, medical research, and international manpower deployment.
Why it mattersThe expansion of the Object Clause provides the legal framework for significant future capacity additions and diversification, which is critical given the company's current low ROCE of 0.9%.
Q1 FY27 Revenue: Rs 22.82 CrQ1 FY27 Net Profit: Rs 2.24 CrNet Worth: Rs 165 CrPromoter Holding: 32.42%Debt: Rs 2 Cr
📅 Short termThe market is likely to view the Q1 profitability and the ambitious expansion plans positively in the coming weeks.
📈 Long termIf the company successfully executes the transition into super-specialty hospitals and diagnostic chains, it could significantly re-rate the business from its current small-cap status.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in diversifying into multiple new healthcare verticals
- Historically low ROCE of 0.9%
Key Highlights
Reported Q1 FY27 revenue of Rs 22.82 Cr and net profit of Rs 2.24 Cr.
Proposed amendment to MoA to allow entry into super-specialty hospitals, medical education, and digital health.
Re-appointed Dr. Muhammed Swadique as Executive Director for a 5-year term ending August 2031.
Appointed Mr. Aboobaker Vattamkandathil as Independent Director, bringing 20 years of finance and reinsurance experience.
Promoter holding increased by 4.85% to reach 32.42% as of the latest filing.
👀 What to Watch
Monitor the 35th Annual General Meeting on September 16, 2026, for shareholder approval of the business object expansion and any subsequent announcements regarding new hospital projects.
Abate As Industries: Rs 23.09 Cr Subsidiary Revenue in Q1; Re-appoints Directors for 5 Years
Abate As Industries approved its Q1 FY27 results and a series of key leadership re-appointments for five-year terms. The company reported that its three subsidiaries contributed Rs 23.09 cr in revenue and Rs 2.08 cr in PAT for the quarter. Significantly, the board proposed an alteration to the Main Object clause of the Memorandum of Association, suggesting a potential shift or expansion in business focus. The 35th Annual General Meeting is scheduled for September 16, 2026, to formalize these changes.
Confidence: HIGH
What changedThe company has secured leadership continuity for the next five years and initiated a process to change its primary business objectives in its charter.
Why it mattersLeadership stability is confirmed, but the proposed MoA change is the most critical factor as it may allow the company to diversify or pivot its business model away from its current hospital/healthcare focus.
Subsidiary Revenue (Q1): Rs 23.09 crSubsidiary PAT (Q1): Rs 2.08 crSubsidiary Assets vs Net Worth: ~56.7%Director Re-appointment Term: 5 yearsAGM Date: September 16, 2026
📅 Short termThe stock may react to the Q1 earnings performance; however, the management re-appointments provide near-term administrative stability.
📈 Long termThe structural significance depends on the details of the MoA object change, which could redefine the company's growth trajectory over the coming years.
⚠ Risk flags
- Significant 12-month price decline of 57.9%
- Potential business pivot risk associated with MoA object change
Key Highlights
Re-appointment of Dr. Muhammed Swadique as Executive Director for a 5-year term until August 13, 2031.
Three subsidiaries reported combined revenue of Rs 23.09 cr and PAT of Rs 2.08 cr for the quarter ended June 30, 2026.
Total assets of subsidiaries reached Rs 93.64 cr, representing approximately 56.7% of the company's Rs 165 cr net worth.
Proposed alteration of the Main Object clause (Clause III(A)(1)) of the Memorandum of Association.
35th Annual General Meeting (AGM) scheduled for September 16, 2026, via video conferencing.
👀 What to Watch
Investors should review the upcoming AGM notice to understand the specific details of the proposed change to the 'Main Object' clause, as this indicates the company's future strategic direction.
Abate As Industries Reports Q1 Cons. Revenue of ₹23.08 Cr; Appoints New Independent Director
Abate As Industries approved its Q1 FY27 results, reporting a consolidated revenue of ₹23.08 crore and a net profit of ₹2.08 crore. The board appointed Mr. Aboobaker Vattamkandathil, a reinsurance professional with over 20 years of experience, as an Additional Independent Director for a 5-year term. Crucially, the company proposed an alteration to its Memorandum of Association (MoA) Main Object clause, suggesting a potential strategic shift. The 35th Annual General Meeting (AGM) is scheduled for September 16, 2026, to seek shareholder approval for these changes and director re-appointments.
Confidence: HIGH
What changedThe company has added a new Independent Director with international finance experience and initiated a formal process to change its primary business objectives.
Why it mattersThe MoA change is significant as it may allow the company to diversify beyond its current hospital industry focus. The Q1 results provide a baseline for the performance of its three subsidiaries.
Consolidated Revenue (Q1): ₹23.08 crConsolidated PAT (Q1): ₹2.08 crSubsidiary Assets: ₹93.64 crPromoter Holding: 32.42%AGM Date: 16th September 2026
📅 Short termThe stock may see minor activity based on the Q1 earnings report, though the long-term price trend has been significantly negative (-57.9% over 12 months).
📈 Long termThe structural significance depends on the proposed MoA changes; a shift in business focus could re-rate the company if it moves into higher-margin segments.
⚠ Risk flags
- Significant 12-month price decline of 57.9%
- Relatively low promoter holding at 32.4%
- Uncertainty regarding the new business objects in the MoA
Key Highlights
Consolidated revenue for the quarter ended June 30, 2026, reached ₹23.08 crore.
Consolidated net profit after tax for the quarter stood at ₹2.08 crore.
Total assets of the three subsidiaries included in consolidation were reported at ₹93.64 crore.
Mr. Aboobaker Vattamkandathil appointed as Independent Director for a 5-year term starting August 13, 2026.
Proposed alteration of the Main Object clause in the Memorandum of Association to be voted on at the AGM.
👀 What to Watch
Investors should review the upcoming AGM notice to understand the specific details of the proposed 'Main Object' clause alteration, as this indicates the company's future business direction.
Abate As Industries Proposes Major MoA Expansion into Multi-Specialty Healthcare
Abate As Industries has proposed a comprehensive alteration to its Memorandum of Association (MoA) to pivot towards a broader healthcare model, including super-specialty hospitals, diagnostic centers, and medical device manufacturing. The board has also approved the Q1 FY27 results and scheduled the 35th Annual General Meeting (AGM) for September 16, 2026. Management stability is reinforced with the re-appointment of Executive Director Dr. Muhammed Swadique for a five-year term. This strategic shift aims to align the company with high-growth healthcare verticals.
Confidence: HIGH
What changedThe company is formally expanding its legal mandate to operate across the entire healthcare value chain, including hospital management, consultancy, and medical manufacturing.
Why it mattersThis provides the legal framework necessary for the company to diversify its revenue streams and scale operations in the healthcare sector, leveraging its Rs 165 Cr net worth.
AGM Date: September 16, 2026Director Re-appointment Term: 5 yearsPromoter Holding: 32.42%Net Worth: Rs 165 CrDebt: Rs 2 Cr
📅 Short termThe market may view the strategic clarity and management continuity as positive, though the stock has faced significant pressure over the last 12 months.
📈 Long termThe expansion into super-specialty healthcare and medical manufacturing represents a structural pivot that could re-rate the business if execution follows the MoA changes.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in entering highly competitive super-specialty healthcare segments
- Historical 12-month price return of -57.9%
- Small market presence relative to industry peers
Key Highlights
Proposed alteration of MoA to include establishing super-specialty hospitals, pathology labs, and medical device trading
Re-appointment of Dr. Muhammed Swadique as Executive Director for a 5-year term ending August 13, 2031
35th Annual General Meeting (AGM) scheduled for September 16, 2026, at 03:00 PM
Appointment of Mr. Aboobaker Vattamkandathil, a finance professional with 20+ years of experience, as Independent Director
Promoter holding recently increased from 27.57% to 32.42% as of March 2026
👀 What to Watch
Monitor the shareholder vote on the MoA alteration at the upcoming AGM and look for subsequent announcements regarding specific capital expenditure or project timelines for new hospital facilities.
Abate As Industries Proposes Expansion of Healthcare Objects and Re-appoints Key Directors
Abate As Industries approved its Q1 FY27 financial results and scheduled its 35th Annual General Meeting (AGM) for September 16, 2026. A significant proposal was made to alter the Memorandum of Association (MoA) to broaden the company's scope into multi-speciality hospitals, diagnostic centers, and medical device manufacturing. The board also re-appointed Dr. Muhammed Swadique as Executive Director and appointed a new Independent Director with 20+ years of insurance experience. Despite a healthy net worth of ₹165 Cr and low debt of ₹2 Cr, the company faces a low ROCE of 0.9%.
Confidence: HIGH
What changedThe company is broadening its legal framework to enter diverse healthcare segments and has secured its leadership team for the next five years.
Why it mattersExpanding the Object Clause is a prerequisite for diversification into high-growth healthcare verticals, which may be necessary to improve the company's historical financial performance and stock returns.
AGM Date: September 16, 2026Director Term: 5 yearsNet Worth: ₹165 CrDebt: ₹2 CrPromoter Holding: 32.42%
📅 Short termThe stock may see limited movement as the MoA changes are enabling provisions rather than immediate revenue-generating events; focus will be on the Q1 results.
📈 Long termThe structural shift toward integrated healthcare and medical devices could be significant if the company successfully deploys its ₹165 Cr net worth into higher-yielding assets.
⚠ Risk flags
- Low ROCE of 0.9%
- Significant 12-month price decline of 57.9%
- Execution risk in diversifying into complex medical device manufacturing
Key Highlights
Proposed expansion of MoA to include super-speciality hospitals, diagnostic centers, and medical device manufacturing
35th Annual General Meeting scheduled for September 16, 2026, via video conferencing
Re-appointment of Dr. Muhammed Swadique as Executive Director for a 5-year term until August 13, 2031
Appointment of Mr. Aboobaker Vattamkandathil as Independent Director for a 5-year term
Company maintains a low Debt-to-Equity ratio of 0.01 based on ₹2 Cr debt and ₹165 Cr net worth
👀 What to Watch
Investors should monitor the upcoming AGM for specific details on the execution timeline and capital allocation for the proposed healthcare expansion, given the current low ROCE of 0.9%.
